{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:57:11Z","timestamp":1793159831909,"version":"4.5.0"},"reference-count":39,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"unspecified","delay-in-days":35,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["4-22-PDFPM-06"],"award-info":[{"award-number":["4-22-PDFPM-06"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["K12TR004416"],"award-info":[{"award-number":["K12TR004416"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG056479"],"award-info":[{"award-number":["R01AG056479"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30DK124723"],"award-info":[{"award-number":["P30DK124723"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2025,9,12]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Preclinical studies suggest a potential link between glucagon-like peptide 1 receptor agonists (GLP-1RA) and thyroid cancer (TC), yet it is unclear if this risk translates to humans.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Research design and methods<\/jats:title>\n                  <jats:p>We estimated the comparative effect of incretin-based therapies (GLP-1RA and dipeptidyl-peptidase-4 inhibitors (DPP-4i)) versus sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on TC incidence among US older adults with type 2 diabetes. We defined TC as a thyroidectomy followed by \u22652 separate diagnoses codes for malignant neoplasm of thyroid gland within 90 days. We estimated adjusted 3-year cumulative risk differences of TC (aRDs) with 95% CIs using weighted Kaplan-Meier survival functions, and adjusted HRs using weighted Cox models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 73\u2009388 new users in the GLP-1RA versus SGLT-2i cohort (mean age 72.4 years, men: 48.3%) and 106\u2009274 in the DPP-4i versus SGLT-2i cohort (mean age 74.6 years, men: 44.9%). At 3 years and a median duration of treatment of 0.82\u20131.15 years, the aRD for GLP-1RA versus SGLT-2i for TC was \u221223 per 10\u2009000 (95% CI: \u221251 to 4) and the aRD for DPP-4i versus SGLT-2i was \u22122 per 10\u2009000 (95% CI: \u221217 to 13). Secondary and sensitivity analyses were consistent.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study of US Medicare beneficiaries with type 2 diabetes suggests that the initiation of incretin-based therapies may not increase the 3-year risk of TC compared with initiation of SGLT-2i. This finding offers reassurance for short-term use but does not eliminate the possibility of increased long-term or subtype-specific risks.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjdrc-2025-005090","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T07:55:13Z","timestamp":1759823713000},"page":"e005090","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Investigating the association between incretin-based therapies and thyroid cancer incidence among US Medicare beneficiaries with diabetes"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8840-025X","authenticated-orcid":false,"given":"Clement O","family":"Acheampong","sequence":"first","affiliation":[{"name":"Department of Epidemiology, The University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9723-3876","authenticated-orcid":false,"given":"John B","family":"Buse","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5894-9054","authenticated-orcid":false,"given":"Klara R","family":"Klein","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence T","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology and Endocrine Surgery, Department of Surgery, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA"},{"name":"Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Evron","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2701-101X","authenticated-orcid":false,"given":"Anna R","family":"Kahkoska","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA"},{"name":"Department of Nutrition, The University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, The University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0980-8896","authenticated-orcid":false,"given":"Tiansheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, The University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Pate","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, The University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Leese","sequence":"additional","affiliation":[{"name":"NC TraCS Institute, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9204-7177","authenticated-orcid":false,"given":"Til","family":"St\u00fcrmer","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, The University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"2025100700550615000_13.5.e005090.1","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/j.jcjd.2017.10.034","article-title":"Pharmacologic Glycemic Management of Type 2 Diabetes in Adults","volume":"42","author":"Lipscombe","year":"2018","journal-title":"Can J Diabetes"},{"key":"2025100700550615000_13.5.e005090.2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.34757"},{"key":"2025100700550615000_13.5.e005090.3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2407"},{"key":"2025100700550615000_13.5.e005090.4","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-1272"},{"key":"2025100700550615000_13.5.e005090.5","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s13340-018-0352-4","article-title":"Diabetes mellitus and thyroid diseases","volume":"9","author":"Nishi","year":"2018","journal-title":"Diabetol Int"},{"key":"2025100700550615000_13.5.e005090.6","doi-asserted-by":"crossref","first-page":"645563","DOI":"10.3389\/fendo.2021.645563","article-title":"Safety of Semaglutide","volume":"12","author":"Smits","year":"2021","journal-title":"Front Endocrinol"},{"key":"2025100700550615000_13.5.e005090.7","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.011395"},{"key":"2025100700550615000_13.5.e005090.8","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-1148"},{"key":"2025100700550615000_13.5.e005090.9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7570\/jomes20059","article-title":"Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes","volume":"30","author":"Seo","year":"2021","journal-title":"J Obes Metab Syndr"},{"key":"2025100700550615000_13.5.e005090.10","doi-asserted-by":"crossref","first-page":"927859","DOI":"10.3389\/fendo.2022.927859","article-title":"Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials","volume":"13","author":"Hu","year":"2022","journal-title":"Front Endocrinol"},{"key":"2025100700550615000_13.5.e005090.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2012.09.008"},{"key":"2025100700550615000_13.5.e005090.12","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1825"},{"key":"2025100700550615000_13.5.e005090.13","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.2147\/DMSO.S305496","article-title":"Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population","volume":"Volume 14","author":"Funch","year":"2021","journal-title":"DMSO"},{"key":"2025100700550615000_13.5.e005090.14","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13597"},{"key":"2025100700550615000_13.5.e005090.15","doi-asserted-by":"publisher","DOI":"10.1177\/2042098612446473"},{"key":"2025100700550615000_13.5.e005090.16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15292"},{"key":"2025100700550615000_13.5.e005090.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078225","article-title":"Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study","volume":"385","author":"Pasternak","year":"2024","journal-title":"BMJ"},{"key":"2025100700550615000_13.5.e005090.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-07921-2"},{"key":"2025100700550615000_13.5.e005090.19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/thy.2024.0387","article-title":"Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study","volume":"35","author":"Baxter","year":"2025","journal-title":"Thyroid"},{"key":"2025100700550615000_13.5.e005090.20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/jamaoto.2024.4852","article-title":"GLP-1RA Use and Thyroid Cancer Risk","volume":"151","author":"Brito","year":"2025","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2025100700550615000_13.5.e005090.21","unstructured":"About cms. CMS. Available: https:\/\/www.cms.gov\/about-cms [Accessed 12 Dec 2023]."},{"key":"2025100700550615000_13.5.e005090.22","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-017-2259-3","article-title":"Performance of claims-based algorithms for identifying incident thyroid cancer in commercial health plan enrollees receiving antidiabetic drug therapies","volume":"17","author":"Funch","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"2025100700550615000_13.5.e005090.23","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-007-0131-1"},{"key":"2025100700550615000_13.5.e005090.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2023.05.004"},{"key":"2025100700550615000_13.5.e005090.25","doi-asserted-by":"publisher","DOI":"10.7326\/M18-3079"},{"key":"2025100700550615000_13.5.e005090.26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/pds.4145","article-title":"New use of prescription drugs prior to a cancer diagnosis","volume":"26","author":"Potteg\u00e5rd","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025100700550615000_13.5.e005090.27","doi-asserted-by":"publisher","DOI":"10.1097\/01.EDE.0000081989.82616.7d"},{"key":"2025100700550615000_13.5.e005090.28","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"2025100700550615000_13.5.e005090.29","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3386"},{"key":"2025100700550615000_13.5.e005090.30","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwu122"},{"key":"2025100700550615000_13.5.e005090.31","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8471"},{"key":"2025100700550615000_13.5.e005090.32","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-021-00778-w"},{"key":"2025100700550615000_13.5.e005090.33","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/pds.5665","article-title":"Achieving comparability in glycemic control between antidiabetic treatment strategies in pregnancy when using real world data","volume":"32","author":"Cesta","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025100700550615000_13.5.e005090.34","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq198"},{"key":"2025100700550615000_13.5.e005090.35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"key":"2025100700550615000_13.5.e005090.36","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0052"},{"key":"2025100700550615000_13.5.e005090.37","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1016\/S0002-9343(00)00338-7","article-title":"Combining sulfonylureas and other oral agents","volume":"108 Suppl 6a","author":"Riddle","year":"2000","journal-title":"Am J Med"},{"key":"2025100700550615000_13.5.e005090.38","unstructured":"Thyroid Cancer. American thyroid association. Available: https:\/\/www.thyroid.org\/thyroid-cancer\/ [Accessed 25 Aug 2025]."},{"key":"2025100700550615000_13.5.e005090.39","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3100"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2025-005090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T07:55:18Z","timestamp":1759823718000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2025-005090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10,6]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/bmjdrc-2025-005090"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2025-005090","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}